Telix Q3 Revenue US$245M (+19%); Narrows FY26 R&D Guidance, Confirms >US$1B FY26
TLX sits 66% above its 52-week low of $6.28.
Summary
Telix posted Q3 2026 revenue of US$245M, up 19% (Precision Medicine +30% to US$201M), reaffirmed FY26 revenue above US$1B and narrowed R&D guidance to US$240M-$260M. The filing also details the US$1.65B ITM merger consideration and sets a December 1, 2026 shareholder meeting.
Key Events · Earnings and Guidance · TLX
-
Q3 Revenue Up 19% to US$245M
Group revenue rose 19% year-over-year from US$206M, though it was roughly flat versus Q2 2026's US$247M on expected summer seasonality (U.S. dose volumes +1% QoQ).
-
Precision Medicine Jumps 30%
Precision Medicine revenue reached US$201M, up 30% from US$155M, driven by Gozellix and Illuccix; TMS third-party revenue fell 6% to US$44M.
-
FY26 Guidance Reaffirmed, R&D Narrowed
FY 2026 revenue and other income expected above US$1B, with revenue tracking to the upper end of US$950M-$970M plus US$40M other income; R&D guidance tightened to US$240M-$260M from US$230M-$270M.
-
ITM Merger Terms Quantified
US$1.65B upfront cash-free/debt-free, about US$1.25B in Telix ADRs to ITM holders, and up to US$700M contingent on ITM-11 milestones; shareholder vote expected December 1, 2026 (AEDT).
Analysis · TLX · Life Sciences
Q3 group revenue of US$245M rose 19% year-over-year, with Precision Medicine up 30% to US$201M on Gozellix and Illuccix demand. The quarter was flat sequentially (US$247M in Q2) as expected summer seasonality held U.S. dose volumes to +1% quarter-over-quarter, but management flagged a stronger September exit rate. Telix reaffirmed FY 2026 revenue and other income above US$1B, with revenue tracking toward the upper end of the US$950M-$970M range plus US$40M other income, and tightened R&D spend guidance to US$240M-$260M from US$230M-$270M — a narrower band that implies slightly lower peak spend. The filing also puts hard numbers on the previously announced ITM merger: US$1.65B upfront on a cash-free, debt-free basis, roughly US$1.25B payable in Telix ADRs, and up to US$700M contingent on ITM-11 approvals and sales, with a shareholder meeting expected December 1, 2026. Pipeline updates include OPTIMAL-PSMA completing 120-patient enrollment (readout H1 2027), IPAX-2 hitting its primary endpoint at two 5 GBq cycles with no dose-limiting toxicities, and the Zircaix BLA resubmission still pending after the corrected CRL.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 29.2% of the 1544 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TLX was trading at $10.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $6.28 to $13.11. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.